- Mizuho rides to the rescue after a report from SA contributor Gravity Research tanked Avanir Pharmaceuticals (AVNR) Wednesday.
- Analyst Mario Corso thinks Gravity is "off the mark."
- Mizuho apparently has a different take on Nuedexta off-label marketing and AVNR's chances in a patent lawsuit.
- AVNR +2.5% premarket
From other sites
at Nasdaq.com (Jan 6, 2015)
Top 4 NASDAQ Stocks In The Drugs Generic Industry With The Highest EPS Growth Forecast For Next 5 Yearsat Benzinga.com (Dec 29, 2014)
Pre-Market Most Active for Dec 19, 2014 : ALLY, BBRY, BP, AVNR, TNK, PBR, OREX, BHP, SDRL, QQQ, AAPL, IMGNat Nasdaq.com (Dec 19, 2014)
at CNBC.com (Dec 3, 2014)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs